Welcome to our dedicated page for IDEXX Laboratories news (Ticker: IDXX), a resource for investors and traders seeking the latest updates and insights on IDEXX Laboratories stock.
IDEXX Laboratories (IDXX) delivers essential diagnostic solutions and practice management tools for veterinary professionals worldwide. This dedicated news hub provides investors and industry stakeholders with timely updates on corporate developments shaping animal healthcare innovation.
Access official press releases and verified news covering financial results, product launches, regulatory milestones, and strategic partnerships. Our curated collection ensures transparent tracking of IDXX's advancements in in-clinic testing systems, reference laboratory services, and integrated practice software solutions.
Key updates include earnings announcements, diagnostic technology innovations, livestock health initiatives, and global expansion efforts. Bookmark this page for efficient monitoring of developments affecting veterinary diagnostics markets and IDXX's position as a leader in animal health solutions.
IDEXX Laboratories, Inc. (NASDAQ: IDXX) announces the release date for its 2022 fourth quarter and full-year financial results, set for February 6, 2023, before market open. A conference call for analysts will occur at 8:30 a.m. ET on the same day. Investors can access a live webcast of the call and review materials via the IDEXX investor relations page. An archived version will be available after 1:00 p.m. ET on that day. IDEXX is a leader in pet healthcare with over 10,000 employees, delivering diagnostic products and services worldwide.
IDEXX Laboratories (NASDAQ: IDXX) will participate in the Goldman Sachs Healthcare CEOs Unscripted Conference on January 5, 2023, at 1:15 pm ET. Jay Mazelsky, President and CEO, will engage in a fireside chat during the event. The live audio webcast can be accessed through the IDEXX website, with an archived edition available post-event. IDEXX is a leader in pet healthcare innovation, aiming to enhance veterinary medicine and ensure safety in milk and water globally.
IDEXX Laboratories reported third quarter 2022 revenue of $842 million, marking a 4% increase as reported and 8% organically. Growth was supported by a 5% rise in CAG Diagnostics recurring revenue and record premium instrument placements, which rose 10%. Earnings per share (EPS) reached $2.15, reflecting a 6% reported increase. The company adjusted its 2022 revenue guidance to 3.5%-4.5% growth. EPS guidance was updated to $7.74-$7.98, incorporating foreign currency impacts. Strong demand in companion animal healthcare and innovative solutions contributed to these results.
IDEXX Laboratories, a leader in pet healthcare innovation, will release its 2022 third-quarter results on November 1, 2022, before the market opens. An analyst conference call is scheduled for 8:30 a.m. ET on the same day. The call can be accessed via a live webcast on the IDEXX website, with an archived version available after 1:00 p.m. ET for one year. IDEXX is a member of the S&P 500® Index, employs over 10,000 people, and serves customers in over 175 countries.
IDEXX Laboratories reported second quarter revenues of $861 million, reflecting a 4% increase overall and 6.5% organic growth, driven by strong demand in the CAG Diagnostics segment, which grew 4% reported and 7% organically. The company achieved record placements of premium instruments, boosting the global installed base by 15%. Despite these gains, EPS fell 33% to $1.56 due to $80 million in R&D investments. IDEXX revised its full-year revenue guidance to 3% - 5.5% growth, reflecting macroeconomic risks.
IDEXX Laboratories, a leader in pet healthcare innovation, will release its 2022 second quarter financial results on August 2, 2022, before market opening. An analyst conference call is scheduled for 8:30 a.m. ET on the same day.
A live webcast will be accessible via the IDEXX website, with an archived version available post-event for one year. This event illustrates IDEXX's ongoing commitment to transparency and investor engagement, following their track record in diagnostic and software solutions that benefit veterinary practices globally.
IDEXX Laboratories (NASDAQ: IDXX) announced new testing services to enhance veterinary care, effective September 2022. Key additions include Fecal Dx antigen testing for flea tapeworm detection, FGF-23 kidney biomarker testing for managing chronic kidney disease in cats, and next-day PCR Direct testing services. These innovations aim to improve diagnostics, enable earlier intervention in critical cases, and support veterinarians in their treatment plans, thereby advancing pet healthcare standards.
IDEXX Laboratories, a leader in veterinary diagnostics, will participate in the Stifel Jaws & Paws Conference on June 1, 2022, at 1:50 pm (EDT). President Jay Mazelsky and CFO Brian McKeon will join a fireside chat. A live audio webcast can be accessed via IDEXX's website. Additionally, IDEXX will host its 2022 Investor Day on August 11, 2022, at its headquarters in Westbrook, Maine, from 8:00 am to 12:00 pm (EDT). More details will follow closer to the event date.
IDEXX Laboratories reported an 8% revenue growth for Q1 2022, driven by CAG Diagnostics recurring revenue growth of 8% reported and 9% organic. Strong demand resulted in a 19% reported and 22% organic growth in CAG Diagnostics capital instrument revenue. However, EPS declined by 3% as reported, while it increased 3% on a comparable basis. The company adjusted its full-year guidance, anticipating 5.5%-8% reported growth, impacted by reduced veterinary clinical visits and foreign exchange rates. Key financial metrics include an updated EPS outlook of $8.11 - $8.35.
IDEXX Laboratories, Inc. (NASDAQ: IDXX) has announced the release of its 2022 first quarter financial results, scheduled for May 4, 2022, before market opening. An analyst conference call will follow at 8:30 a.m. ET, accessible via a live webcast on the IDEXX website. The archived webcast will be available after 1:00 p.m. ET and will remain for one year. IDEXX, a leader in veterinary diagnostics and healthcare innovation, employs over 10,000 people and serves customers in over 175 countries worldwide.
